Business Context and Reporting Period
This Form 8-K Current Report was filed by Vanda Pharmaceuticals Inc. on April 15, 2010, regarding corporate governance changes effective April 21, 2010. The filing addresses the departure of a director and the election of a new director to the Board.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and director compensation arrangements rather than financial performance.
Material Changes
- Director Resignation: Brian K. Halak, Ph.D., resigned from the Board of Directors, the Audit Committee, and his role as Chairman of the Nominating/Corporate Governance Committee.
- Committee Leadership Change: Richard W. Dugan was appointed as the new Chairman of the Nominating/Corporate Governance Committee.
- New Director Election: Vincent J. Milano was elected as a Class II Director and appointed to the Audit Committee to fill the vacancy left by Dr. Halak.
Guidance, Outlook, and Compensation
The filing details the compensatory arrangements for the new director, Mr. Milano, but contains no financial guidance, outlook, or discussion of risks and contingencies.
- Initial Grant: Option to purchase 35,000 shares of common stock at the closing price on April 21, 2010, vesting monthly over four years.
- Annual Fee: $25,000 per year.
- Meeting Fees: $2,500 for in-person Board meetings ($1,250 for telephone) and $1,000 for Audit Committee meetings.
- Annual Grant: Eligible for an option to purchase 15,000 shares upon the conclusion of each annual stockholder meeting.
- Indemnification: Mr. Milano will enter into an indemnification agreement consistent with those held by other directors.
Investor Verification Checklist
- Verify the independence status of Vincent J. Milano given his role as CEO and Chairman of ViroPharma Incorporated.
- Confirm the vesting schedule and exercise price of the 35,000 share option granted to Mr. Milano.
- Review the Company's Definitive Proxy Statement for the 2009 annual meeting for full details on the outside director compensation program.
- Check subsequent filings for any updates regarding the transition of the Audit Committee following Dr. Halak's departure.